David Matthew Reive

Prior to joining Sprigings Intellectual Property Law, David was a partner at a national law firm, where he was leader of the intellectual property group from 2015 to 2022. David has spoken extensively on many issues related to patent litigation and pharmaceutical patents.

Trademark opposition case regarding the marks JOS and JOS Design (Application Nos. 2337004 and 2272713).

Application under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations regarding empagliflozin.

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,652,442 and 2,771,403 (lenvatinib).

Counsel to defendants in patent infringement action relating to use of imazamox herbicides regarding Patent No. 2,447,445.

Counsel to respondent trademark owner in expungement proceedings regarding trademark TMA822855. Successfully applied for dismissal of proceeding due to undue and inexcusable delay (2024 FC 579).